Currently Viewing
CURE New Issue Alert: Immunotherapy Special Issue
October 03, 2019 – Katie Kosko and Brielle Benyon
My Gene Counsel White Paper Reveals Need for Patient Advocacy in Genetic Testing Follow-Up
October 01, 2019 – Kristie L. Kahl
CURE's Top 5 Stories: September 2019
October 01, 2019 – Jessica Skarzynski
How Has Cancer Changed the Way Patients Live Their Lives?
September 30, 2019 – Jessica Skarzynski
Leading the Fight Against Ovarian Cancer
September 30, 2019 – Audra Moran
FDA Expands ColoGuard Approval: What This Means for Individuals 45 and Older
September 27, 2019 – Kristie L. Kahl
Blood Cancer Awareness Month: What You Need to Know
September 27, 2019 – Jessica Skarzynski
Friday Frontline: Cancer Updates, Research and Education on September 27, 2019
September 27, 2019 – Katie Kosko
FDA Approves Frontline Darzalex Regimen to Treat Patients With Multiple Myeloma
September 26, 2019 – Katie Kosko

CURE New Issue Alert: Immunotherapy Special Issue

Here’s a look at what’s inside our 2019 Immunotherapy special issue.
BY Katie Kosko and Brielle Benyon
PUBLISHED October 03, 2019
Here’s a look at what’s inside our 2019 Immunotherapy special issue:

Immunotherapy has been a game-changer for patients with cancer and researchers. But how did this type of treatment come to life? This issue takes you back more than 100 years to see the evolution of immuno-oncology.

Next, the first immunotherapy for patients with metastatic triple-negative breast cancer is now approved by the FDA. Read the stories of two women who feel a renewed sense of hope and are happy to kick chemotherapy to the curb.

And, CAR-T cell therapy is the latest type of immunotherapy to offer great rewards — but with great risks. Walk in the shoes of a non-Hodgkin lymphoma survivor as he shares his firsthand experience and what he wished he had known before treatment.

To read these stories and more, check out the full issue online

Or, ensure you don’t miss a story when you subscribe to new issue alerts.

And, as always, thanks for reading.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Immunotherapy CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In